AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12161484
Drug: raloxifene 60
RxNorm normalized name: raloxifene 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: raloxifene 60 mg/d and 120 mg/d
Trial: 8700340
Drug: Acarbose 300
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acarbose 300 mg/day for 12 weeks with hypocaloric diet
Trial: 1810616
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment with long-leg plaster (group B)
Trial: 6622929
Drug: Prednisolone plus
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone plus azathioprine 50 mg daily
Trial: 30132529
Drug: Glucosamine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucosamine (2 g/day for 16 weeks)
Trial: 27916140
Drug: Moderate alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moderate alcohol consumption (2 cans of beer, 660 mL, ∼26 g alcohol)
Trial: 25076468
Drug: Contralateral balanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contralateral balanced multifocal contact lens combination (CBMCLC)
Trial: 22402677
Drug: Knee Outcome
RxNorm normalized name: Bos taurus knee joint preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Knee Outcome Survey activities of daily living subscale (KOS‐ADL)
Trial: 19470315
Drug: Brief strategic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief strategic family therapy (BSFT)
Trial: 2901181
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg once daily of methimazole
Trial: 2901181
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg 3 times daily of methimazole
Trial: 25182412
Drug: Real tVNS
RxNorm normalized name: TVN-102
DrugBank: TVN-102 (DB16990)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real tVNS (transcutaneous vagus nerve stimulation) administered at left external acoustic meatus for 60 min
Trial: 21575032
Drug: 5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 μg TTX (given t.i.d.)
Trial: 21575032
Drug: 10 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 μg TTX (given t.i.d.)
Trial: 14499444
Drug: Topical morphine
RxNorm normalized name: morphine Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical morphine mouthwash (2 per thousand solution)
Trial: 14499444
Drug: Topical morphine
RxNorm normalized name: morphine Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical morphine mouthwash (1 per thousand solution)
Trial: 10872650
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg ibuprofen lysine
Trial: 9195171
Drug: 0.5% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% ropivacaine 40 ml (200 mg)
Trial: 9195171
Drug: 0.25% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% ropivacaine 40 ml (100 mg)
Trial: 9195171
Drug: Saline 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 40 ml
Trial: 1287837
Drug: Continuous bupivacaine
RxNorm normalized name: Uniphyllin Continus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous bupivacaine infusion
Trial: 1287837
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion (Control) in patients with COAD
Trial: 1287837
Drug: Continuous bupivacaine
RxNorm normalized name: Uniphyllin Continus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous bupivacaine infusion in patients with COAD
Trial: 1287837
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion (Control) in patients without COAD
Trial: 4040887
Drug: pafenolol 25
RxNorm normalized name: atenolol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pafenolol 25 mg
Trial: 4040887
Drug: pafenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pafenolol 50 mg
Trial: 20181302
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 to 40 mg per day plus IPT adapted to BPD (IPT-BPD)
Trial: 20181302
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 to 40 mg per day plus clinical management
Trial: 19060514
Drug: Intra-articular sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular sodium hyaluronate injections (Orthovisc)
Trial: 11119731
Drug: Oral HRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral HRT (2 mg of estradiol on days 1-12, 2 mg of estradiol plus 1 mg of norethisterone acetate on days 13-22, and 1 mg of estradiol on days 23-28; n = 21)
Trial: 11119731
Drug: Transdermal HRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal HRT (50 microg/d of estradiol on days 1-28 and 250 microg/d of norethisterone acetate on days 15-28; n = 21)
Trial: 29125933
Drug: Rigid fixation
RxNorm normalized name: Pinus rigida pollen
DrugBank: Pinus rigida pollen (DB10896)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rigid fixation with 4 L miniplates placed bilaterally in the maxilla after distraction device removal.
Trial: 28277060
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAPT) with clopidogrel in addition to aspirin
Trial: 25516635
Drug: 3-weekly doses
RxNorm normalized name: selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 3-weekly doses of nanoparticle albumin-bound paclitaxel
Trial: 25516635
Drug: weekly doses
RxNorm normalized name: selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: weekly doses of nanoparticle albumin-bound paclitaxel
Trial: 25516635
Drug: weekly doses
RxNorm normalized name: selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: weekly doses of Cremophor-based paclitaxel
Trial: 18640467
Drug: Combination lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination lidocaine 20 mg and dexamethasone 6 mg
Trial: 14526299
Drug: 400 microg
RxNorm normalized name: Fentanyl 400 microgram buccal film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 microg of oral misoprostol every 8 hours
Trial: 14526299
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (oral and vaginal misoprostol)
Trial: 18853315
Drug: Topical lomefloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lomefloxacin 0.3%
Trial: 6802100
Drug: Dextroamphetamine sulfate
RxNorm normalized name: Dextroamphetamine Sulfate
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextroamphetamine sulfate (20 mg) after pimozide pretreatment (5 weeks)
Trial: 6802100
Drug: Dextroamphetamine sulfate
RxNorm normalized name: Dextroamphetamine Sulfate
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextroamphetamine sulfate (20 mg) after placebo pretreatment
Trial: 6802100
Drug: Dextroamphetamine sulfate
RxNorm normalized name: Dextroamphetamine Sulfate
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextroamphetamine sulfate (20 mg) after pimozide pretreatment
Trial: 6802100
Drug: Dextroamphetamine sulfate
RxNorm normalized name: Dextroamphetamine Sulfate
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextroamphetamine sulfate (20 mg)
Trial: 30507214
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) anger-reduction treatment for 12 weeks
Trial: 23340248
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g polydextrose (control)
Trial: 23340248
Drug: 6.3 g
RxNorm normalized name: OCTINOXATE 6.3 g in 100 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.3 g polydextrose
Trial: 23340248
Drug: 12.5 g
RxNorm normalized name: glycerin 12.5 GM per 20.4 ML Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 g polydextrose
Trial: 23340248
Drug: 25 g
RxNorm normalized name: AndroGel 1.25 g Packets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 g polydextrose
Trial: 21079110
Drug: Extended arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extended arm (evidence-based practice bundle including omission of mechanical bowel preparation, preoperative and intraoperative warming, supplemental oxygen, intraoperative intravenous fluid restriction, use of a surgical wound protector)
Trial: 17680178
Drug: Heparin anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin anticoagulation at 180 U x kg(‐1) plus 3000 U every 30 min for OPCAB patients, along with rectal aspirin 650 mg during the procedure.
Trial: 17680178
Drug: Heparin anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin anticoagulation regimen in OPCAB patients.
Trial: 17680178
Drug: Heparin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin and protamine doses in OPCAB group.
Trial: 10806855
Drug: Subcutaneous rhEpo
RxNorm normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous rhEpo 150 U/kg.time, three times a week for 6 weeks
Trial: 10806855
Drug: Subcutaneous rhEpo
RxNorm normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous rhEpo 250 U/kg.time, three times a week for 6 weeks
Trial: 7778529
Drug: Delapril 30
RxNorm normalized name: Delapril
DrugBank: Delapril (DB13312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delapril 30 mg twice daily
Trial: 312976
Drug: Solu‐Medrol (methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solu‐Medrol (methylprednisolone sodium succinate) 1 g/liter
Trial: 24333889
Drug: Three months
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three months of drug therapy for comorbid mental disorders
Trial: 10401950
Drug: CHDF circuit
RxNorm normalized name: BREATHING CIRCUIT W/MOUTHPIECE,STANDARD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHDF circuit with a haemofilter made of polymethylmethacrylate membrane primed with 50 mg nafamostat in 500 ml saline, continuous injection of 0.5 mg/kg per h nafamostat, 700 ml/h of dialysis fluid and 1000 ml/h of filtrate fluid
Trial: 2620043
Drug: Mebeverine (135
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mebeverine (135 mg, two capsules, three times daily)
Trial: 2620043
Drug: Mefenamic acid
RxNorm normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mefenamic acid (250 mg, two capsules, three times daily)
Trial: 2620043
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two capsules, three times daily)
Trial: 1091532
Drug: Wheat bran
RxNorm normalized name: Wheat bran
DrugBank: Wheat bran (DB10685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat bran (20 g daily)
Trial: 31021882
Drug: Serratus plane
RxNorm normalized name: Fucus serratus extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serratus plane block (SPB) with 25 ml of ropivacaine 0.5%
Trial: 25478975
Drug: Remifentanil (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (0.75 μg/kg over 30 seconds)
Trial: 25478975
Drug: Ketamine (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.25 mg/kg over 30 seconds)
Trial: 25478975
Drug: Propofol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (0.5 mg/kg over 30 seconds)
Trial: 19483370
Drug: Vegetable tablets
RxNorm normalized name: Hydrogenated Vegetable Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vegetable tablets (10 g/trial)
Trial: 19483370
Drug: Control tablets
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control tablets (10 g/trial)
Trial: 11761819
Drug: Inhaled ambroxol
RxNorm normalized name: ambroxol
DrugBank: Ambroxol (DB06742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled ambroxol
Trial: 8131253
Drug: 15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg mefloquine
Trial: 8131253
Drug: 25 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/kg mefloquine
Trial: 8131253
Drug: Quinine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine (30 mg.kg‐1.day‐1) + Tetracycline (25 mg.kg‐1.day‐1) for re-treatment
Trial: 2481671
Drug: Chemotherapy (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (specific agents not detailed)
Trial: 29046732
Drug: Group 1
RxNorm normalized name: Chlamydophila psittaci biogroup 1 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 (G1): 300 g of vegetables and legumes containing on average 191 μg/day of folate and 1 hazelnut oil capsule
Trial: 29046732
Drug: Group 2
RxNorm normalized name: Chlamydophila psittaci biogroup 2 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2 (G2): 300 g of vegetables and legumes containing on average 191 μg/day of folate and 1 placebo capsule
Trial: 29046732
Drug: Group 3
RxNorm normalized name: Chlamydophila psittaci biogroup 3 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 3 (G3): 300 g of vegetables and legumes containing on average 90 μg/day of folate and 1 hazelnut oil capsule
Trial: 25305223
Drug: Riboflavin supplementation
RxNorm normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Riboflavin supplementation (10 mg/day)
Trial: 8346830
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine (0.5, 1.0, 1.5, or 2.0 mg/kg)
Trial: 25147364
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine (2 mg/kg)
Trial: 31620802
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg ixekizumab every 2 weeks for 12 weeks, then 80 mg open-label ixekizumab every 4 weeks through Week 52
Trial: 31620802
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 12 weeks, then 80 mg open-label ixekizumab every 4 weeks through Week 52
Trial: 30041702
Drug: Single intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous dose of co-amoxiclav
Trial: 26265075
Drug: Elastic Resistance
RxNorm normalized name: elastin
DrugBank: Elastin (human) (DB15364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elastic Resistance Training (ERT) twice a week for 8 weeks
Trial: 21410627
Drug: sitagliptin/metformin FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sitagliptin/metformin FDC 50/500 mg bid
Trial: 21410627
Drug: metformin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin monotherapy 500 mg bid (uptitrated to 1000 mg bid)
Trial: 21410627
Drug: sitagliptin/metformin FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sitagliptin/metformin FDC
Trial: 23427864
Drug: metformin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin monotherapy
Trial: 16532455
Drug: Gabapentin treatment
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin treatment (600-2,700 mg/day)
Trial: 14612979
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg beta-carotene or lycopene supplementation
Trial: 14612979
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg beta-carotene or lycopene supplementation
Trial: 1346817
Drug: Standard heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard heparin (to achieve an activated partial thromboplastin time of 1.5 to 2.0 times the pretreatment value)
Trial: 1346817
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (adjusted only for body weight) for 10 days
Trial: 27553712
Drug: Oxytocin (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin (24 IU) administered intranasally
Trial: 24471659
Drug: Intravenous parecoxib
RxNorm normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Intravenous parecoxib 40 mg then oral celecoxib 400 mg at 12 hours (group PC)
Trial: 24471659
Drug: Intravenous paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous paracetamol 2 g then oral 1 g six-hourly (group PA)
Trial: 24471659
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of intravenous parecoxib, oral celecoxib, and paracetamol (group PCPA)
Trial: 22752297
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone acetate (AA) 1,000 mg orally once daily + prednisone 5 mg orally twice daily
Trial: 17676319
Drug: Voriconazole 400
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Voriconazole 400 mg twice daily on the first day and 200 mg twice daily on the second day
Trial: 17676319
Drug: Fluconazole 400
RxNorm normalized name: fluconazole 400 MG in 200 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 400 mg on the first day and 200 mg on the second day
Trial: 12135535
Drug: 75 mg/d
RxNorm normalized name: Lyllana 0.075 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg/d venlafaxine
Trial: 2332919
Drug: Diltiazem hydrochloride
RxNorm normalized name: Diltiazem Hydrochloride
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diltiazem hydrochloride (360 mg daily)
Trial: 2332919
Drug: Propranolol hydrochloride
RxNorm normalized name: Propranolol Hydrochloride
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol hydrochloride (240 mg daily)
Trial: 6774359
Drug: Thyrotropin-releasing hormone
RxNorm normalized name: thyrotropin-releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyrotropin-releasing hormone (TRH), 0.5 mg i.v.
Trial: 6774359
Drug: Thyroid hormones
RxNorm normalized name: Thyroid hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroid hormones (TH) pretreatment
Trial: 6774359
Drug: Thyrotropin-releasing hormone
RxNorm normalized name: thyrotropin-releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyrotropin-releasing hormone (TRH) with TH pretreatment
Trial: 31405122
Drug: Lactobacillus gasseri
RxNorm normalized name: Lactobacillus Gasseri
DrugBank: Lactobacillus gasseri (DB16543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus gasseri CP2305 tablets
Trial: 20727237
Drug: Fibre supplement
RxNorm normalized name: Fiore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibre supplement (psyllium)
Trial: 20727237
Drug: Healthy eating
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy eating plus fibre supplement (HLT-FIB)
Trial: 20727237
Drug: Fibre supplement
RxNorm normalized name: Fiore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibre supplement (FIB)
Trial: 19952360
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) treatment in men
Trial: 19952360
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) treatment in women
Trial: 17161934
Drug: Standard preadmission
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard preadmission education (written educational material with non-systematic oral education) (Group B)
Trial: 11157645
Drug: Low-intensity oral
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity oral anticoagulant therapy (targeted INR of 2.5; range, 2.0 to 3.0)
Trial: 11157645
Drug: IV heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV heparin
Trial: 11157645
Drug: Heparin dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin dosage and age (> 70 years)
Trial: 11157645
Drug: LMW heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LMW heparin
Trial: 3371392
Drug: Controlled-release metoprolol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release metoprolol, 100 mg once daily
Trial: 22033512
Drug: Severe-light (S-L)
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Severe-light (S-L)
Trial: 12920415
Drug: Typical antipsychotic
RxNorm normalized name: benzocaine Mucous Membrane Topical Solution [Topicale]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Typical antipsychotic discontinuation (n = 12)
Trial: 12920415
Drug: Typical antipsychotic
RxNorm normalized name: benzocaine Mucous Membrane Topical Solution [Topicale]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Typical antipsychotic continuation (n = 12)
Trial: 10902990
Drug: Energy supplement
RxNorm normalized name: Nutritional Supplement Oral Bar [PROTEIN FORTIFIED ENERGY SUPPLEMENT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy supplement (E) = 1171 kJoule + 12 mg iron
Trial: 10902990
Drug: Supplement (S)
RxNorm normalized name: S-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplement (S) = 104 kJ